Key result
Mono- and trinuclear platinum(II)–N-heterocyclic carbene complexes were synthesized and their in vitro cytotoxicity was evaluated against breast and liver cancer cell lines compared to cisplatin.
Why the study?
Platinum(II) complexes with N-heterocyclic carbene ligands show promise as novel anticancer drugs, but cytotoxicity of trinuclear Pt II-NHC complexes toward cancer cells had not been reported.
The study introduces the synthesis and characterization of novel trinuclear platinum(II)-NHC complexes and evaluates their cytotoxicity against breast and liver cancer cell lines.
First trinuclear Pt(II)–NHC complexes synthesized; leaves open cytotoxicity testing and anticancer translation.
Platinum(II) complexes with N-heterocyclic carbene (NHC) ligands have been demonstrated as intriguing and promising foundations to construct novel metal-based anticancer drugs. To the best of our knowledge, there is no report of trinuclear Pt II –NHC complexes showcasing cytotoxicity toward cancer cells. Herein, we introduce the synthesis and characterization of the first examples of trinuclear platinum(II) complexes possessing a tris-NHC ligand, along with the corresponding mononuclear complexes. The in vitro cytotoxicity assessment of these complexes is explored against three breast cancer cell lines, 4T1, MDA-MB-231, and MCF-7, and a liver cancer cell line, Hep G2, and the results are compared with values obtained for the standard platinum drug cisplatin.
No takes yet. Share an insight, caveat, or question.
Halder et al. (2025) studied Breast and liver cancer (in vitro cell lines). Mono- and trinuclear platinum(II)–N-heterocyclic carbene complexes vs. Cisplatin was evaluated on In vitro cytotoxicity. Mono- and trinuclear platinum(II)–N-heterocyclic carbene complexes were synthesized and their in vitro cytotoxicity was evaluated against breast and liver cancer cell lines compared to cisplatin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: